Phase 1Status unknownAge-related condition

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

A Phase Ⅰ Clinical Study of TAB014 in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

Sponsor: Lee's Pharmaceutical Limited (Industry)
Enrollment: 24 planned
Conditions: AMD
Interventions: TAB014
Ages: adults, older adults
Registry: NCT03675880

Full record on ClinicalTrials.gov

From the registry

Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.

Primary outcomes

Toxicity associated with TAB014 treatment (possibly, probably, or definitively) occurs within 28 days after a single dose of TAB014.

History

Study completion
Apr 30, 2019
Primary completion
Feb 15, 2019
Last registry update
Sep 26, 2018
Registered
Sep 18, 2018
Started
Jun 15, 2018